Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071510 · ClinicalTrials.gov registry record
Evaluation of the Atlas Genetics io® CTNG System
A clinical trial of Gonorrhea and Chlamydia Trachomatis, sponsored by Binx Health Limited.
- Completed
- Registry status
- 7,128
- Enrollment target
- 10
- Study locations
NCT03071510 is a study of Gonorrhea and Chlamydia Trachomatis that has completed, run by Binx Health Limited. The registered enrollment target is 7,128 participants, above the 733-participant average among 10 other Gonorrhea trials with a reported enrollment target (872% higher). The trial reports 10 study locations across 9 states.
The verdict
NCT03071510, a study of Gonorrhea and Chlamydia Trachomatis, has completed, sponsored by Binx Health Limited.
- COMPLETED
- Registry status
- 7,128 participants
- Enrollment target
- 10
- Study locations
Study Summary
Atlas Genetics io® system results are compared with those obtained from comparator devices.
Conditions Studied
Interventions
- DEVICE Atlas Genetics io® system
Study Locations (10)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Wake Forest Center for Reproductive Medicine - Greensboro
Alabama
- University of Alabama - Birmingham
California
- AIDS Healthcare Foundation - Los Angeles
Indiana
- Indiana University - Indianapolis
Louisiana
- Louisiana State University - New Orleans
Maryland
- Johns Hopkins University - Baltimore
Mississippi
- University of Mississippi - Jackson
Pennsylvania
- Planned Parenthood Southeastern Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,128 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2019-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03071510
The ClinicalTrials.gov registry entry for NCT03071510 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,128 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 733-participant average among 10 other Gonorrhea trials with a reported enrollment target (872% higher). The listed sponsor is Binx Health Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gonorrhea appearing as the primary indexed condition, and to 1 intervention - of which Atlas Genetics io® system is the first listed.
NCT03071510 reports 10 study locations spanning 9 distinct geographic areas - top geographies include North Carolina, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03071510 about?
NCT03071510 is a clinical study titled "Evaluation of the Atlas Genetics io® CTNG System". Atlas Genetics io® system results are compared with those obtained from comparator devices.
What is the current status of trial NCT03071510?
This trial is currently completed. The enrollment target is 7,128 participants. The study started on 2017-05-18. Estimated completion is 2019-08-30.
What conditions does trial NCT03071510 study?
This clinical trial studies the following conditions: Gonorrhea, Chlamydia Trachomatis.
What interventions are being tested in trial NCT03071510?
The interventions under investigation include: Atlas Genetics io® system (DEVICE).
Who is sponsoring clinical trial NCT03071510?
This trial is sponsored by Binx Health Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03071510 being conducted?
This trial has 10 study locations across Alabama, California, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gonorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Relationship Education for Reducing HIV Incidence Among SGM
RECRUITING · NA
-
Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision
RECRUITING · NA
-
Online HIV Prevention for Young Male Couples
COMPLETED · Phase 2
-
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
COMPLETED · Phase 2
-
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
COMPLETED · NA
-
Aztreonam for Pharyngeal Gonorrhea
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.